Global Aptamers Market

Aptamers Market Size, Share, Growth Analysis, By Type(Nucleic Acid and Peptide), By Application(Diagnostics, Therapeutics, Research & Development, Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35E2038 | Region: Global | Published Date: September, 2024
Pages: 219 | Tables: 62 | Figures: 77

Aptamers Market Insights

Global Aptamers Market size was valued at USD 155 million in 2022 and is poised to grow from USD 182.59 million in 2023 to USD 677.08 million by 2031, growing at a CAGR of 17.80% during the forecast period (2024-2031).

Many researchers are interested in aptamers because of their competitive advantages in recent developments in the production, purification, and drug delivery for killing target cells. Small molecular size, low immunogenicity, low manufacturing costs, and less side effects compared to antibodies are a few of the benefits; these factors may encourage the development of innovative aptamers, leading to market expansion.

Due to several genetic variations, there are presently no extremely effective therapies for infections, despite extensive attempts. The SELEX technology-based diagnostic kits and assays have the capacity to produce high-affinity neutralizers. As a result, it is anticipated that the release of diagnostic kits on the market will spur market expansion. Aptamer is a second-generation diagnostic kit for healthcare that was created utilising DNA aptamer-based technology.

It is inexpensive, chemically synthesised, and a growing diagnostic kit. Soma Logic stated in March 2022 that it had begun employing the SomaScan Assay to analyse 210 million protein measurements from 30,000 samples for the European Prospective Investigation into Cancer and Nutrition (EPIC) research. Through a deeper understanding of the disease, researchers will be better able to forecast cancer, which will help the market flourish by meeting the growing demand.

Due to their tiny size, high specificity, selectivity, and efficacy, diagnostic solutions based on aptamers are the preferred option among diagnostic and pathology labs for the diagnosis of disease at the cellular level. Around 27.5 million individuals are anticipated to receive a cancer diagnosis by the year 2040, according to predictions from Cancer Research UK.

US Aptamers Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Aptamers Market size was valued at USD 155 million in 2022 and is poised to grow from USD 182.59 million in 2023 to USD 677.08 million by 2031, growing at a CAGR of 17.80% during the forecast period (2024-2031).

To increase their market share, major players are using tactics including product modification, new product approval, mergers and acquisitions, and geographical growth. These methods are all aimed at improving their current products. Applications of aptamers in therapeutics may find new growth opportunities as a result of such activities. 'Aptamer Group (UK) ', 'Raptamer Discovery Group (US) ', 'Somalogic, Inc. (US) ', 'Aptamer Sciences, Inc. (US) ', 'Aptagen, LLC  (US) ', 'Maravai Lifesciences (US) ', 'Kaneka Corporation (Japan) ', 'NeoVentures Biotechnology Inc. (Canada) ', 'Aptus Biotech (Spain) ', 'Base Pair Biotechnologies (US) ', 'Amsbio (UK) ', 'Novaptech (France) ', 'Bio-Techne (US) ', 'Aptitude Medical Systems (US) ', 'Raybiotech, Inc. (US) ', 'Alpha Diagnostic International, Inc. (US) ', 'Creative Biolabs (US) ', 'Creative Biogene (US) ', 'Vivonics Inc. (US) ', 'Iba Lifesciences GmbH (Germany) ', 'Aptabharat Innovations Pvt. Ltd (India) ', 'Profacgen (US) ', 'Mediven (Germany) ', 'Pure Biologics SA (Poland) ', 'Oak Biosciences, Inc. (US)'

Aptamers play a crucial role in personalized medicine as they can specifically bind to target molecules, including proteins, peptides, and small molecules. The growing emphasis on targeted therapies and precision medicine has led to increased demand for aptamers as they offer advantages such as high specificity, low immunogenicity, and customizable properties. Aptamers enable precise molecular recognition, facilitating the development of personalized treatment strategies.

Focus on SELEX Optimization and Automation : SELEX (Systematic Evolution of Ligands by Exponential Enrichment) is the primary method for aptamer selection. There is a growing focus on optimizing and automating the SELEX process to enhance efficiency, reduce costs, and improve aptamer quality. Advances in high-throughput screening, microfluidics, and robotics are being employed to streamline the aptamer development process, making it more accessible and scalable.

With a market share of 44.48% in 2023, North America region led the aptamers market. The rising incidence of chronic diseases, the region's robust healthcare system, and the growing interest of research labs in the field of aptamers are some of the main drivers of the area's supremacy. Also in April 2022, Noxxon Pharma made the announcement that it would disclose top line results for its NOX-A12 GLORIA study in brain cancer at the annual meeting of the American Society of Clinical Oncology.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Aptamers Market

Report ID: SQMIG35E2038

$5,300
BUY NOW GET FREE SAMPLE